117TH CONGRESS 2D SESSION

# S. 5002

## **AN ACT**

To allow for alternatives to animal testing for purposes of drug and biological product applications.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,

### 1 SECTION 1. SHORT TITLE.

- This Act may be cited as the "FDA Modernization
- 3 Act 2.0".
- 4 SEC. 2. ALTERNATIVES TO ANIMAL TESTING.
- 5 (a) IN GENERAL.—Section 505 of the Federal Food,
- 6 Drug, and Cosmetic Act (21 U.S.C. 355) is amended—
- 7 (1) in subsection (i)—
- 8 (A) in paragraph (1)(A), by striking "pre-
- 9 clinical tests (including tests on animals)" and
- inserting "nonclinical tests"; and
- (B) in paragraph (2)(B), by striking "ani-
- mal" and inserting "nonclinical tests"; and
- 13 (2) after subsection (y), by inserting the fol-
- lowing:
- 15 "(z) Nonclinical Test Defined.—For purposes
- 16 of this section, the term 'nonclinical test' means a test con-
- 17 ducted in vitro, in silico, or in chemico, or a non-human
- 18 in vivo test that occurs before or during the clinical trial
- 19 phase of the investigation of the safety and effectiveness
- 20 of a drug, and may include animal tests, or non-animal
- 21 or human biology-based test methods, such as cell-based
- 22 assays, microphysiological systems, or bioprinted or com-
- 23 puter models.".
- 24 (b) Biosimilar Biological Product Applica-
- 25 TIONS.—Item (bb) of section 351(k)(2)(A)(i)(I) of the

Public Health Service Act (42 U.S.C. 262(k)(2)(A)(i)(I))

is amended to read as follows:

"(bb) an assessment of toxicity (which may rely on, or consist of, a study or studies described in item (aa) or (cc));

and".

Passed the Senate September 29, 2022.

Secretary.

Attest:

# 117th CONGRESS S. 5002

# AN ACT

To allow for alternatives to animal testing for purposes of drug and biological product applications.